An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Quantum-Si to Present at the B. Riley Securities’ Disruptive Biotech Enabling Technologies Virtual Mini Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Quantum-Si Incorporated (NASDAQ: QSI) announced participation in the B. Riley Disruptive Biotech Enabling Technologies Virtual Mini Conference. Scheduled for April 7, 2022, at 10:20 am ET, the presentation will focus on the company's innovative approach to single molecule protein sequencing aimed at revolutionizing proteomics and advancing drug discovery. Interested listeners should contact their B. Riley Securities representatives for access. Quantum-Si’s technology leverages a unique semiconductor chip for enhanced proteomic research.
Positive
None.
Negative
None.
GUILFORD, Conn.--(BUSINESS WIRE)--
Mar. 28, 2022--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing single molecule protein sequencing, today announced that it will be participating in the B. Riley Disruptive Biotech Enabling Technologies Virtual Mini Conference.
Quantum-Si’s management is scheduled to present virtually on Thursday, April 7, 2022 at 10:20 am ET. To listen to the live event, please contact your B. Riley Securities representative with interest.
About Quantum-Si Incorporated Quantum-Si is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single molecule next-generation protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.
